In the MDS bone marrow, normal hematopoietic cell development is impaired via the activation of the interleukin-6 pathway amongst others, which has been shown to impair normal HSCs in vivo, hence promoting the survival and proliferation of MDS clones. This evidence concerns the gene IL6 and myelodysplastic syndrome.